Literature DB >> 11816825

Sarcoidosis: clinical update.

U Costabel1.   

Abstract

Many advances have been made regarding sarcoidosis in the past 2 decades. As a result, sarcoidosis is now defined as a multisystem disorder with a heightened cellular immune response at sites of disease activity in patients with a predisposition for sarcoidosis and a presumed exposure to as yet unknown transmissible environmental agents. Recent International Consensus Statement recommendations regarding diagnosis and therapy have been published. The diagnosis of sarcoidosis is based on a compatible clinical and/or radiological picture, histological evidence of noncaseating granulomas and exclusion of other diseases capable of producing a similar histological or clinical picture. Therapy is based on corticosteroids, although there are indications of valuable alternatives. Except for life- and sight-threatening organ involvement, it should be carefully considered whether the patient might benefit from treatment. For asymptomatic pulmonary sarcoidosis, a watch and wait approach is appropriate; treatment should mainly be considered if symptoms develop or lung function deteriorates.

Entities:  

Mesh:

Year:  2001        PMID: 11816825

Source DB:  PubMed          Journal:  Eur Respir J Suppl        ISSN: 0904-1850


  39 in total

1.  [Bilateral parotid swelling].

Authors:  C Barth; H Sadick; K Hörmann; B A Stuck
Journal:  HNO       Date:  2008-05       Impact factor: 1.284

2.  Experiences and benefits of positron emitted tomography-computed tomography (PET-CT) combined with video-assisted thoracoscopic surgery (VATS) in the diagnosis of Stage 1 sarcoidosis.

Authors:  Shi-Ping Luh; Tzu-Chin Wu; Yao-Tung Wang; Thomas Chang-Yao Tsao; Jia-Yuh Chen
Journal:  J Zhejiang Univ Sci B       Date:  2007-06       Impact factor: 3.066

3.  Spirometry, cardiopulmonary exercise testing and the six-minute walk test results in sarcoidosis patients.

Authors:  Arda Kiani; Alireza Eslaminejad; Mohsen Shafeipour; Fatemeh Razavi; Seyyed Reza Seyyedi; Babak Sharif-Kashani; Habib Emami; Mehrdad Bakhshayesh-Karam; Atefeh Abedini
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

4.  Sarcoidosis as a risk factor for venous thromboembolism.

Authors:  Anna Goljan Geremek; Witold Tomkowski; Marcin Geremek; Elżbieta Puścińska; Grzegorz Małek; Adam Nowiński; Michal Bednarek; Paweł Śliwiński
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 5.  New insights into gastrointestinal and hepatic granulomatous disorders.

Authors:  Majid A Almadi; Abdulrahman M Aljebreen; Faisal M Sanai; Victoria Marcus; Ebtissam S Almeghaiseeb; Subrata Ghosh
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-05       Impact factor: 46.802

6.  Levels of transferrin in bronchoalveolar lavage fluid in sarcoidosis.

Authors:  Masahiko Shigemura; Yasuyuki Nasuhara; Satoshi Konno; Takeshi Hattori; Chikara Shimizu; Kazuhiko Matsuno; Masaharu Nishimura
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

7.  (18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis.

Authors:  Ruth G Keijsers; Jan C Grutters; Heleen van Velzen-Blad; Jules M van den Bosch; Wim J Oyen; Fred J Verzijlbergen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-16       Impact factor: 9.236

8.  A 34-year-old man with cardiac arrhythmias and lymphadenopathy.

Authors:  Nico Abegunewardene; Tommaso Gori; Markus Vosseler; Kai-Helge Schmidt; Christian Taube; Felix Post; Christoph Düber; Karl-Friedrich Kreitner; Thomas Münzel
Journal:  Clin Res Cardiol       Date:  2010-03-09       Impact factor: 5.460

9.  Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients.

Authors:  Esam H Alhamad; Majdy M Idrees; Mohammed O Alanezi; Ahmad A Alboukai; Shaffi Ahmad Shaik
Journal:  Ann Thorac Med       Date:  2010-04       Impact factor: 2.219

10.  BAL fluid cells in newly diagnosed pulmonary sarcoidosis with different clinical activity.

Authors:  Edvardas Danila; Laimute Jurgauskiene; Jolita Norkuniene; Radvile Malickaite
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.